12 citations
,
January 2018 in “Breast Cancer Basic and Clinical Research” This study reported that subcutaneous trastuzumab improved certain symptoms and did not negatively impact health-related quality of life in patients with early or metastatic HER2-overexpressing breast cancer.
June 2026 in “Journal of cancer research updates” This study conducted in an Iraqi oncology setting found generic Palbociclib to have a safety profile consistent with previous data, with observed side effects including high rates of neutropenia and anemia, particularly among patients receiving it with Fulvestrant.
2 citations
,
May 2024 in “The World Journal of Men s Health” This cohort study using real-world data found no significant difference in the risk of developing prostate cancer between finasteride and dutasteride among patients with benign prostatic hyperplasia, despite previous suggestions that dutasteride might be more effective.
4 citations
,
January 2014 in “The Journal of urology/The journal of urology” This study found that folliculin deficient renal cancer cells were more sensitive to irradiation due to increased autophagic cell death, suggesting a potentially enhanced therapeutic approach when combined with autophagy inducers like rapamycin.
39 citations
,
June 2019 in “Frontiers in Endocrinology” This study reported that while both sorafenib and lenvatinib may require dose modifications due to adverse events in treating advanced or metastatic thyroid cancers, key differences in side effect profiles were observed.